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Abstract
Rationale: There remains uncertainty about the role of
corticosteroids in sepsis with clear beneﬁcial effects on shock
duration, but conﬂicting survival effects. Two transcriptomic
sepsis response signatures (SRSs) have been identiﬁed. SRS1 is
relatively immunosuppressed, whereas SRS2 is relatively
immunocompetent.
Objectives:We aimed to categorize patients based on SRS
endotypes to determine if these proﬁles inﬂuenced response to either
norepinephrine or vasopressin, or to corticosteroids in septic shock.
Methods: A post hoc analysis was performed of a double-blind,
randomized clinical trial in septic shock (VANISH [Vasopressin vs.
Norepinephrine as Initial Therapy in Septic Shock]). Patients were
included within 6 hours of onset of shock and were randomized to
receive norepinephrine or vasopressin followed by hydrocortisone or
placebo. Genome-wide gene expression proﬁling was performed and
SRS endotype was determined by a previously established model
using seven discriminant genes.
Measurements and Main Results: Samples were available from
176patients: 83 SRS1 and 93SRS2.Therewas no signiﬁcant interaction
between SRS group and vasopressor assignment (P = 0.50). However,
there was an interaction between assignment to hydrocortisone or
placebo, and SRS endotype (P = 0.02). Hydrocortisone use was
associated with increased mortality in those with an SRS2 phenotype
(odds ratio = 7.9; 95% conﬁdence interval = 1.6–39.9).
Conclusions: Transcriptomic proﬁle at onset of septic shock was
associated with response to corticosteroids. Those with the
immunocompetent SRS2 endotype had signiﬁcantly highermortality
when given corticosteroids compared with placebo.
Clinical trial registered with www.clinicaltrials.gov (ISRCTN20769191).
Keywords: sepsis; norepinephrine; vasopressin; corticosteroids;
transcriptomics
Sepsis is deﬁned as life-threatening organ
dysfunction due to a dysregulated host
response to infection (1), and is a major
global health problem. Current treatment of
septic shock relies on antibiotics, ﬂuids, and
vasopressors. No new or speciﬁc treatments
for sepsis are in routine clinical practice.
Corticosteroids have been proposed as an
adjunctive treatment for septic shock.
However, results of clinical trials have been
contradictory regarding their impact on
outcomes. Recently, two large clinical trials
have been published examining the effect of
corticosteroids on mortality in septic shock.
The ADRENAL (Adjunctive Glucocorticoid
Therapy in Patients with Septic Shock)
study (2) compared a hydrocortisone
infusion to placebo, whereas APROCCHSS
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(Hydrocortisone Plus Fludrocortisone for
Adults with Septic Shock) (3) used a
combination of hydrocortisone and
ﬂudrocortisone. Both showed clear beneﬁts of
corticosteroids on cardiovascular outcomes,
demonstrated by shorter durations of shock;
however, the effects on survival were
inconsistent, with APROCCHSS reporting
improved survival with corticosteroid
treatment and ADRENAL reporting no
difference. We hypothesize that variation in
underlying patient phenotypes may account
for these differences in outcome.
We have previously identiﬁed two
transcriptomic sepsis response signatures
(SRSs) based on genome-wide expression
proﬁling in patients with sepsis with
community acquired pneumonia (4) and
fecal peritonitis (5). SRS1 is a relatively
immunosuppressed phenotype that is
associated with increased mortality, whereas
SRS2 is relatively immunocompetent.
In this report, we describe the
stratiﬁcation of patients enrolled into the
VANISH (Vasopressin vs. Norepinephrine as
Initial Therapy in Septic Shock) clinical trial
(6), comparing norepinephrine to vasopressin
with or without hydrocortisone for the
treatment of septic shock, based on their SRS
endotypes. We aimed to determine if
transcriptomic phenotype was associated
with response to either norepinephrine or
vasopressin, or to corticosteroids.
Methods
Study Design and Sample Collection
Full details of patient selection and treatment
allocation can be found in the online
supplement. Patients were recruited into the
VANISH trial as previously described (6, 7).
The VANISH trial was a factorial (23 2),
multicenter, double-blind, randomized clinical
trial conducted in 18 intensive care units in
the United Kingdom between February 2013
and May 2015, with a primary outcome of
kidney failure–free days up to Day 28. The
trial was approved by the Oxford A research
ethics committee, and written consent was
obtained from patients or their legal
representatives. Adults with septic shock and
who required vasopressors were eligible for
the trial and were recruited within 6 hours of
the onset of septic shock. Patients were
randomized to receive either a blinded
infusion of vasopressin or norepinephrine
(study drug 1), this was titrated to maintain
the target mean arterial pressure. Only if the
maximum infusion rate of study drug 1 was
reached did patients receive the blinded
study drug 2, either hydrocortisone or
placebo, as previously reported (8). Blood
samples for RNA analysis were collected on
the day of enrolment into the trial in 10
centers when research staff members were
available, and RNA was extracted as
described in the online supplement.
Outcomes
The primary outcome for this analysis was
survival at 28 days. Secondary outcomes
were kidney failure–free days up to Day 28,
intensive care unit and hospital mortality,
rates of kidney failure, weaning from
vasopressors for greater than 24 hours, time
to shock reversal, duration of mechanical
ventilation, and mean total Sequential
Organ Failure Assessment score (SOFA).
Statistical Analysis
Patients were allocated to either SRS1 or SRS2
using a generalized linear model based on the
set of seven genes (DYRK2, CCNB1IP1,
TDRD9, ZAP70, ARL14EP, MDC1, and
ADGRE3) derived from the previous study of
patients with sepsis due to community
acquired pneumonia (4, 5). Differential
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At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Several studies investigating
corticosteroids in septic shock have
found beneﬁcial effects on shock
duration. However, effects on survival
are varied, with some studies reporting
a survival advantage but others ﬁnding
no beneﬁt. The role of corticosteroids
in septic shock remains uncertain, and
the reasons for the variation in study
outcomes remain unclear. Recently,
two transcriptomic sepsis response
signatures (SRSs) have been associated
with immune function and outcome in
sepsis.
What This Study Adds to the
Field: This is the ﬁrst study to
examine, in septic shock, the
interaction between SRS endotypes,
and the response to norepinephrine or
vasopressin, or to corticosteroids, in
the context of a randomized trial.
Although SRS endotype had no
inﬂuence on mortality from sepsis
based on vasopressor choice, there
was a signiﬁcant interaction
between SRS endotype and treatment
with hydrocortisone with regard
to mortality. Patients with the
immunocompetent SRS2 endotype
who were treated with corticosteroids
had poorer survival than those given
placebo. SRS endotype at the onset of
septic shock appears to inﬂuence
response to corticosteroids. This
ﬁnding may account for the variation
in survival beneﬁt attributed to
corticosteroids if varying proportions
of the SRS endoypes were recruited
into previous trials.
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expression analysis was performed using the
limma R package (9). For the primary
outcome, SRS endotype and drug interaction
was explored using binary logistic regression
with an interaction term, and differences in
survival were displayed using Kaplan-Meier
curves using log-rank tests for signiﬁcance,
and Renyi tests when survival curves crossed.
As numbers were low in some treatment
subgroups, the analysis was repeated using
exact logistic regression analysis as a
sensitivity analysis (10). As randomization
was not stratiﬁed by SRS endotype and RNA
was only analyzed in a sample of patients,
there may be imbalances of potential
confounders (age, sex, acute illness score
[APACHE (Acute Physiology and Chronic
Health Evaluation) II score]), and
comorbidities (ischemic heart disease, severe
chronic obstructive pulmonary disease,
chronic renal failure, cirrhosis, cancer,
immunosuppression, and diabetes), so
multivariable logistic regression was
performed as a sensitivity analysis (5). For
both comparisons, vasopressin versus
norepinephrine and hydrocortisone versus
placebo, only patients who received the study
drug as allocated were included, as described
in the per-protocol analysis in the primary
analysis (6). Further details of the statistical
analysis can be found in the online
supplement.
Results
Samples were available from 177 patients,
Figure 1, but 1 patient was excluded, as the
timing of the blood sample was recorded as
9 days after inclusion. The baseline
characteristics of these patients were similar
to the total trial population, and to those
who did not have RNA sampling (see Table
E1 in the online supplement). The 28-day
mortality was also similar in those who did
(27%) and did not (31%) have RNA
samples taken (P = 0.43). Among these 176
patients, 83 (47%) were classiﬁed as SRS1
and 93 (53%) as SRS2. We compared global
gene expression differences between the
Allocated to
Vasopressin + Hydrocortisone
(n=106)
Allocated to
Vasopressin + Placebo
(n=107)
Allocated to
Norepinephrine + Hydrocortisone
(n=102)
Allocated to
Norepinephrine + Placebo
(n=106)
Sampled (n=45) Sampled (n=46) Sampled (n=43) Sampled (n=42)
Included in Study drug 1 x SRS
analysis (n=45)
Included in Study drug 1 x SRS
analysis (n=46)
Included in Study drug 1 x SRS
analysis (n=43)
Included in Study drug 1 x SRS
analysis (n=41)
Included in Study drug 2 x SRS
analysis (n=32)
Included in Study drug 2 x SRS
analysis (n=38)
Included in Study drug 2 x SRS
analysis (n=26)
Included in Study drug 2 x SRS
analysis (n=21)
Received open-label
vasopressin +
hydrocortisone (n=1)
Did not receive study
drug 2 (n=18)
Received open-label
hydrocortisone (n=2)
Did not receive
study drug 2 (n=17)
Did not receive
study drug 2 (n=8)
Did not receive
study drug 2 (n=13)
Randomized (n=421)
Consent declined (n=1)
Patient ineligible and
not given study drug (n=4)
Refused ongoing
participation (n=1)
No RNA sample collected
(n=54)
Excluded owing to sample
timing (n=1)
Consent declined (n=1)
Patient ineligible
and not given study
drug  (n=2)
No RNA sample
collected (n=58)
Consent declined (n=1)
No RNA sample
collected (n=58)
Consent declined (n=2)
Patient ineligible and
not given study drug (n=1)
No RNA sample
collected (n=61)
Figure 1. Recruitment, randomization, treatment allocation, and RNA sampling in the VANISH (Vasopressin vs. Norepinephrine as Initial Therapy in Septic
Shock) clinical trial. SRS = sepsis response signature.
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SRS endotypes in the VANISH patients to
those observed in the derivation study of
sepsis due to community-acquired
pneumonia (4). We found that SRS, rather
than study cohort, was the major driver of
the observed variation in gene expression
(Figure E1A), and that the differential gene
expression results were strongly correlated
(Pearson’s r = 0.858, P, 2.23 10216;
Figure E1B). Patients with SRS1 and SRS2
endotypes were similar with regard to
demographics and baseline characteristics,
with only a small difference in rates of
ischemic heart disease (higher in SRS2)
and serum lactate (higher in SRS1)
(Table 1). Baseline characteristics were
also similar when patients were stratiﬁed by
SRS and treatment allocation (Table E2).
The effect of vasopressor treatment on
mortality at 28 days did not differ
statistically between SRS groups
(vasopressin vs. norepinephrine in SRS1,
odds ratio [OR] = 1.50, 95% conﬁdence
interval [CI] = 0.58–3.88; SRS2, OR = 0.94,
95% CI = 0.36–2.46; interaction P = 0.50).
However, in those patients who
received the second study drug, either
hydrocortisone or placebo, there was
a statistically signiﬁcant interaction
between treatment and SRS endotype
(hydrocortisone vs. placebo in SRS1, OR =
0.85, 95% CI = 0.30–2.43; SRS2, OR = 7.9,
95% CI = 1.6–39.9; interaction P = 0.02).
Table 1. Comparison of Baseline Characteristics of Patients with Sepsis Response Signature 1 and 2 Phenotypes
Characteristics SRS1 SRS2 P Value
n 83 93 —
Age, median (IQR), yr 66 (53–78) 63 (53–75) 0.40
Men, n/total (%) 55/83 (66) 54/93 (58) 0.26
Weight, median (IQR), kg 75 (65–88) 74 (61–92) 0.72
BMI, median (IQR) 26 (23–31) 27 (22–32) 0.68
White race, n/total (%) 70/83 (84) 74/93 (80) 0.41
Recent surgical history, n/total (%) 15/83 (18) 12/93 (13) 0.34
APACHE II score, median (IQR) 23 (20–30) 24 (19–31) 0.70
Preexisting conditions, n/total (%)
Ischemic heart disease 8/83 (10) 21/93 (23) 0.02
Severe COPD 5/83 (6) 5/93 (5) 0.85
Chronic kidney failure 4/83 (5) 4/93 (4) 0.87
Cirrhosis 3/83 (4) 8/93 (9) 0.17
Cancer 12/83 (14) 10/93 (11) 0.46
Immunocompromised 7/83 (8) 3/93 (3) 0.14
Diabetes 16/83 (19) 24/93 (26) 0.30
Organ failure, n/total (%)
Respiratory 33/83 (40) 31/91 (34) 0.44
Kidney 18/83 (22) 22/93 (24) 0.76
Liver 4/73 (5) 8/82 (10) 0.32
Hematological 4/79 (5) 5/92 (5) 0.91
Neurological 27/79 (34) 29/90 (32) 0.79
Physiological variables, median (IQR)
Mean arterial pressure, mm Hg 70.0 (64.0–76.0) 67.0 (60.5–75.0) 0.16
Heart rate, beats/min 96.0 (85.0–112.0) 92.0 (80.5–104.0) 0.10
Central venous pressure, mm Hg 14 (10–19) 13 (9–18) 0.09
Lactate, mmol/L 2.8 (1.8–4.9) 1.9 (1.3–3.3) 0.001
PaO2/FIO2, mm Hg 197 (122–322) 195 (137–299) 0.96
Creatinine, mg/dl 1.3 (1.0–2.1) 1.4 (0.8–2.3) 0.64
Bilirubin, mg/dl 1.0 (0.5–2.1) 0.7 (0.5–1.3) 0.10
Platelets, 3103/ml 192 (121–267) 187 (120–291) 0.98
GCS 14.0 (6.0–15.0) 13.5 (3.0–15.0) 0.70
Mechanical ventilation, n/total (%) 42/83 (51) 54/93 (58) 0.32
Renal replacement therapy, n/total (%) 3/83 (4) 2/93 (2) 0.56
Volume of i.v. ﬂuid in previous 4 h, median (IQR), ml 1,255 (547–2,054) 1,003 (557–1,665) 0.09
Patients receiving open-label vasopressor at
randomization, n/total (%)
72/83 (87) 81/93 (87) 0.95
Time from onset of shock to receiving ﬁrst study
drug, median (IQR), h
4.0 (1.8–5.5) 3.4 (2.0–4.9) 0.44
Norepinephrine dose at randomization, median (IQR),
mg/kg/min
0.16 (0.10–0.28) 0.14 (0.08–0.25) 0.25
Source of infection, n/total (%)
Lung 32/82 (39) 45/91 (49) 0.17
Abdomen 21/82 (26) 15/91 (16) 0.14
Soft tissue or line 1/82 (1) 4/91 (4) 0.21
Other 28/82 (34) 27/91 (30) 0.53
Definition of abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; COPD = chronic obstructive pulmonary
disease; GCS =Glasgow Coma Score; IQR = interquartile range; i.v. = intravenous; SRS = sepsis response signature.
P values are from Mann-Whitney U tests for continuous variables and Pearson’s x2 tests for binary variables. Missing data are shown in Table E3 in the online
supplement. For the APACHE score, range 0–72, a higher score corresponds to more severe illness and a higher risk of death; for GCS, range 3–15, a lower score
corresponds to a greater depression of consciousness; BMI was calculated as weight in kilograms divided by height in meters squared. Bold type indicates P, 0.05.
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Kaplan-Meier survival curves are shown
in Figure 2. Similar results were
obtained using exact logistic regression
(hydrocortisone vs. placebo in SRS1, OR =
0.85, 95% CI = 0.26–2.73; SRS2, OR = 7.67,
95% CI = 1.45–78.8; interaction P = 0.046).
After adjustment for age, sex, disease
severity (APACHE II), and comorbidities in
multiple logistic regression, hydrocortisone
use continued to be associated with
increased mortality in those with an
SRS2 phenotype (adjusted OR = 8.3, 95%
CI = 1.4–47.8), and the treatment by
SRS endotype interaction remained
signiﬁcant (interaction P = 0.03).
In patients who received placebo, mortality
was lower in those with the SRS2 compared
with SRS1 endotype (unadjusted OR=0.15,
95% CI= 0.03–0.76, P=0.02; adjusted OR=
0.13, 95% CI = 0.02–0.74, P = 0.02;
Figure E2), consistent with mortality
differences associated with SRS
endotypes reported previously (4, 5).
Rates and duration of renal failure, and
proportions of patients successfully
weaned off vasopressors were similar based
on SRS and study drug 2 combination
(Table 2). Within both SRS1 and SRS2, those
patients given hydrocortisone tended to be
weaned more quickly from vasopressors
(SRS1, HR = 1.3, 95% CI = 0.8–2.3; SRS2,
HR = 1.1, 95% CI = 0.6–1.9), although the
CIs clearly include 1. Rates of all serious
adverse events in the study were the same
between SRS endotypes (6 [7%] SRS1 vs. 6
[6%] SRS2, P = 0.84).
Number at risk
39 32 31 31 29
44 39 35 30 29
14 21 2870
Vasopressin
Norepinephrine
Time (days)
+
+
+
+
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p = 0.53
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1.00
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+
p = 0.007
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14 21 2870
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SRS2
Figure 2. Kaplan-Meier survival curves comparing survival with (A) norepinephrine (red line) and vasopressin (green line) and (B) hydrocortisone (red line)
and placebo (green line) in sepsis response signature (SRS) 1 and SRS2. Crosses represent censored patients (n = 2 for SRS1 vasopressin, n = 1 for SRS1
placebo, and n = 1 for SRS1 hydrocortisone; all other patients were censored at death or Day 29).
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Discussion
We were able to identify the two previously
identiﬁed SRS endotypes within this septic
shock population due to diverse etiologies in
the VANISH clinical trial. In this study, a
higher proportion of patients had the SRS1
endotype (47%) than in either the derivation
(41%) or validation (35%) cohorts described
in the original study (4). However, the
original data were derived from a sepsis
population where only a portion had
septic shock, with under half requiring
vasopressors. Vasopressor use and SOFA
score were higher in SRS1 patients in the
derivation study, suggesting more severe
disease. It is therefore unsurprising that, in
a sicker population of patients, all of whom
had septic shock, the SRS1 endotype is
more commonly represented. Importantly,
although the two SRS endotypes have
previously been described in both
community-acquired pneumonia (4) and
fecal peritonitis (5), this is the ﬁrst time the
endotypes have been demonstrated in
patients with sepsis due to multiple
different sources of infection.
Transcriptomic proﬁle at the onset of
septic shock was associated with response to
corticosteroids, but not vasopressin or
norepinephrine. Those patients with the
SRS2 endotype had signiﬁcantly higher
mortality when given corticosteroids
compared with placebo. However, this effect
on mortality was not seen in those with the
SRS1 endotype. Previous work (4, 5)
demonstrated that the SRS2 endotype was
associated with a signiﬁcantly lower
mortality rate than SRS1. In patients with
sepsis with pneumonia, 28-day mortality
was 17% in SRS2 compared with 27% in
SRS1 (4), and, in fecal peritonitis, 28-day
mortality was 7.2% versus 20.8% for SRS2
and SRS1, respectively (5). This pattern was
again seen in the current study when only
those patients randomized to placebo were
considered, where 28-day mortality was
lower in SRS2 (8%) compared with SRS1
(37%). As inclusion/exclusion criteria and
illness severity vary between different
studies, actual mortality rates will inevitably
vary.
Steroids have a clear beneﬁt on time-to-
shock resolution, reported in multiple
clinical trials (2, 3, 8, 11). Despite this
improvement in an important physiological
measure, the overall effect on patient
survival has been inconsistent between
trials. Differences in the mortality effects of
steroids in the recent ADRENAL (2) and
APROCCHSS (3) trials may be explained
by the current ﬁndings. If these trials
recruited different proportions of patients
with the two SRS endotypes, a trial with a
greater proportion of SRS2 patients may
ﬁnd no survival advantage or may ﬁnd
harm due to steroids in septic shock. In
observational studies, SRS1 has been
associated with higher mortality than SRS2,
and similar effects were seen in placebo
patients in this trial. Overall, the mortality
in the ADRENAL trial was lower than that
seen in the APROCCHSS trial (28% vs.
46%, respectively, at Day 90), perhaps
suggesting that a higher proportion of SRS2
patients may have been recruited. If the
SRS2 patients are harmed with steroid
treatment, it may explain why, overall,
no mortality beneﬁt was seen in the
ADRENAL trial, despite improvement in
shock resolution. Interestingly, the duration
of shock tended to be shorter among both
SRS1 and SRS2 patients successfully
weaned from vasopressors, although the
CIs are wide, possibly due to the small
numbers in each subgroup.
Because of the many mechanisms of
action of corticosteroids, we can only
speculate as to why the effect of steroids
on mortality should vary between SRS
endotypes. The SRS1 endotype has been
shown to be a relatively immunosuppressed
phenotype with features of endotoxin
tolerance, T cell exhaustion, and
downregulation of major histocompatibility
class (MHC) II antigens, and is associated
with higher mortality rates. The SRS2
endotype in contrast is relatively more
immunocompetent and associated with lower
mortality rates. Of particular interest is the
upregulation of MHC II in SRS2 (4).
Reduction in HLA-DR expression in sepsis
has been associated with higher rates of
nosocomial infection and worse survival (12),
so it is plausible that improvement in antigen
Table 2. Comparison of Outcomes of Patients with Sepsis Response Signature 1 and 2 Phenotypes Given Either Hydrocortisone or
Placebo as Study Drug 2
SRS1 SRS2 P Value for
InteractionHydrocortisone Placebo Hydrocortisone Placebo
n 27 35 31 24
Kidney failure–free days, median (IQR), d 25 (1–28) 25 (9–28) 25 (4–28) 28 (25–28) 0.43*
28-d mortality, n/total (%) 9/27 (33) 13/35 (37) 13/31 (42) 2/24 (8) 0.02†
ICU mortality, n/total (%) 7/27 (26) 9/35 (26) 11/31 (35) 2/24 (8) 0.08†
Hospital mortality, n/total (%) 8/27 (30) 12/35 (34) 13/31 (42) 2/24 (8) 0.02†
Kidney failure, n/total (%) 13/27 (48) 19/35 (54) 17/31 (55) 10/24 (42) 0.30†
No. weaned from vasopressors for
.24 h, n/total (%)
25/27 (93) 31/35 (89) 28/31 (90) 23/24 (96) 0.36†
Time to shock reversal, median (IQR), h 30.6 (18.1–77.7) 43.8 (21.5–91.5) 58.9 (36.1–82.3) 89.5 (31.5–122.0) 0.60‡
Duration of mechanical ventilation,
median (IQR), d
3.0 (2.0–12.0) 6.0 (2.0–11.5) 6.0 (2.0–14.5) 9.0 (6.0–20.0) 0.67*
Mean total SOFA score, median (IQR) 5.7 (3.6–9.0) 4.9 (3.6–7.2) 5.6 (3.7–8.3) 4.7 (3.5–6.3) 0.72x
Definition of abbreviations: IQR = interquartile range; SOFA = Sequential Organ Failure Assessment score; SRS = sepsis response signature.
Bold type indicates P , 0.05.
*From the aligned rank transform test.
†From logistic regression.
‡From Cox regression, treating deaths as never having the event of interest. Results were similar treating death as a competing risk.
xFrom linear regression, applying a square root transform to the outcome.
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presentation improves immune function and
bacterial clearance in the SRS2 group,
improving survival compared with SRS1.
However, corticosteroids are recognized to
downregulate MHC II (12–14), which could
provide a mechanism by which this protective
advantage is removed. Corticosteroids also
have actions affecting NF-kB, T cells, and
apoptosis (15, 16), all of which showed
evidence of differential expression between
the SRS endotypes. Altered modulation of
these pathways could account for different
degrees of immunosuppression caused
by corticosteroids between the SRS endotypes.
It is therefore possible that corticosteroids may
have beneﬁcial cardiovascular effects in all
patients with septic shock, but that the well-
known immunosuppressive adverse effects of
corticosteroids are only realized in the
SRS2 patients. Immune dysfunction is
recognized to increase the risk of nosocomial
infection and to be associated with higher
rates of mortality (17), yet clinical scoring
systems, such as SOFA, do not include the
immune system. This may account for why
no difference in total SOFA score was seen
despite mortality differences between
treatment groups in our study.
Transcriptomic proﬁles in sepsis and
response to corticosteroid therapy have been
studied in children (18). In this previous
study, a subgroup of patients was identiﬁed
using RNA expression that was also
associated with worse outcomes when
patients were treated with corticosteroids,
although this subgroup was the more
immunosuppressed phenotype. However, as
previously described (5, 19), the gene
expression proﬁles appear to be different in
adult and pediatric populations, with those
in children being based, in part, on genes
linked to glucocorticoid receptors. In the
pediatric study corticosteroid treatment was
based on physician choice rather than
randomized allocation as in this clinical trial.
This study does have limitations. It is a
post hoc analysis of samples collected as
part of a clinical trial. Research blood
sampling was not available in all centers,
and, due to the emergency nature of the
trial and the short recruitment window
(maximum 6 h), it was not logistically
possible to collect samples from all patients,
thus limiting the sample size. However,
the subset of patients in this analysis had
similar baseline characteristics to the
overall trial population, and the result
was robust to adjustment for potential
confounders and the use of statistical
methods to account for small numbers.
Although the analysis was post hoc, we used
predeﬁned endotype deﬁnitions based on
previously published work and derived and
validated in independent cohorts (4, 5).
Importantly, treatment allocation was
randomized and double blinded. Although
the SRS endotypes are described according
to their presumed immunological effects,
this is based on gene expression data, and
the absolute functional implications of the
endotypes are still to be established. It is
plausible that corticosteroids interact with
SRS endotypes in ways that cannot be
appreciated from transcriptomic data alone.
Although further work is required to
validate these ﬁndings and to better understand
the utility of endotype assignment based on
transcriptomic proﬁles in sepsis, our ﬁndings
suggest that SRS endotypes should be used
in future biomarker-guided trials of
corticosteroids in septic shock. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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